p/e ratio actually was only 19x at the issue price. not that...

p/e ratio actually was only 19x at the issue price. not that high p/e at all. just for clarification telstra is 14-15times, and CSL is over 20 times. none have the growth profile of VIT.

here is the info:

Clearly you have to exclude the musashi legacy cost, and add the $4m ebitda, as at IPO it included musashi. Too much noise in financials are confusing people, but its clearly below in highlighted:

So its p/e ratio at 2.10 was only 19x. At 1.85, last close, its only 16.7 times which is approaching telstra p/e. As we know telstra is not a growth company at all.

Also its not just the p/e. At 2.10 its market cap was a measly $292m, compared with the china vitamin market of $20bn and growing. Low market cap offers a lot of leverage .Its 19 p/e was based on low penetration currently into china. So any success will get a lot of upside.

Currently i hold VIT and numerous china stocks which all are being shorted for no reason. VIT appears to be oversold.

There are a few things VIT can do a bit better -like Nutralife hasnt yet penetrated chemist warehouse or Priceline. Their other brands are there no problem. Also marketing they've guided a bit more attention. Their trilogy contract loss was meaningless long term IMO only $1.5M ebitda which can be replaced by own brands.